skip to main content
Idioma:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Busca Simples
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: nível superior: Recursos Online remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Primary CNS Lymphoma
Primary CNS Lymphoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Primary CNS Lymphoma

Grommes, Christian ; DeAngelis, Lisa M

Journal of clinical oncology, 2017-07, Vol.35 (21), p.2410-2418 [Periódico revisado por pares]

United States: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
2
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells
Material Type:
Artigo 		Adicionar ao Meu Espaço

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells

Hirayama, Alexandre V. ; Gauthier, Jordan ; Hay, Kevin A. ; Voutsinas, Jenna M. ; Wu, Qian ; Gooley, Ted ; Li, Daniel ; Cherian, Sindhu ; Chen, Xueyan ; Pender, Barbara S. ; Hawkins, Reed M. ; Vakil, Aesha ; Steinmetz, Rachel N. ; Acharya, Utkarsh H. ; Cassaday, Ryan D. ; Chapuis, Aude G. ; Dhawale, Tejaswini M. ; Hendrie, Paul C. ; Kiem, Hans-Peter ; Lynch, Ryan C. ; Ramos, Jorge ; Shadman, Mazyar ; Till, Brian G. ; Riddell, Stanley R. ; Maloney, David G. ; Turtle, Cameron J.

Blood, 2019-04, Vol.133 (17), p.1876-1887 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
3
Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL
Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL
Material Type:
Artigo 		Adicionar ao Meu Espaço

Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL

Rossi, John ; Paczkowski, Patrick ; Shen, Yueh-Wei ; Morse, Kevin ; Flynn, Brianna ; Kaiser, Alaina ; Ng, Colin ; Gallatin, Kyle ; Cain, Tom ; Fan, Rong ; Mackay, Sean ; Heath, James R. ; Rosenberg, Steven A. ; Kochenderfer, James N. ; Zhou, Jing ; Bot, Adrian

Blood, 2018-08, Vol.132 (8), p.804-814 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
4
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma

Flinn, Ian W ; Miller, Carole B ; Ardeshna, Kirit M ; Tetreault, Scott ; Assouline, Sarit E ; Mayer, Jiri ; Merli, Michele ; Lunin, Scott D ; Pettitt, Andrew R ; Nagy, Zoltan ; Tournilhac, Olivier ; Abou-Nassar, Karem-Etienne ; Crump, Michael ; Jacobsen, Eric D ; de Vos, Sven ; Kelly, Virginia M ; Shi, Weiliang ; Steelman, Lori ; Le, NgocDiep ; Weaver, David T ; Lustgarten, Stephanie ; Wagner-Johnston, Nina D ; Zinzani, Pier Luigi

Journal of clinical oncology, 2019-04, Vol.37 (11), p.912-922 [Periódico revisado por pares]

United States: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
5
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma

Knutson, Sarah K ; Kawano, Satoshi ; Minoshima, Yukinori ; Warholic, Natalie M ; Huang, Kuan-Chun ; Xiao, Yonghong ; Kadowaki, Tadashi ; Uesugi, Mai ; Kuznetsov, Galina ; Kumar, Namita ; Wigle, Tim J ; Klaus, Christine R ; Allain, Christina J ; Raimondi, Alejandra ; Waters, Nigel J ; Smith, Jesse J ; Porter-Scott, Margaret ; Chesworth, Richard ; Moyer, Mikel P ; Copeland, Robert A ; Richon, Victoria M ; Uenaka, Toshimitsu ; Pollock, Roy M ; Kuntz, Kevin W ; Yokoi, Akira ; Keilhack, Heike

Molecular cancer therapeutics, 2014-04, Vol.13 (4), p.842-854 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por
6
ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies
ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies
Material Type:
Artigo 		Adicionar ao Meu Espaço

ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies

Zammarchi, Francesca ; Corbett, Simon ; Adams, Lauren ; Tyrer, Peter C. ; Kiakos, Konstantinos ; Janghra, Narinder ; Marafioti, Teresa ; Britten, Charles E. ; Havenith, Carin E.G. ; Chivers, Simon ; D'Hooge, Francois ; Williams, David G. ; Tiberghien, Arnaud ; Howard, Philip W. ; Hartley, John A. ; van Berkel, Patrick H.

Blood, 2018-03, Vol.131 (10), p.1094-1105 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
7
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
Material Type:
Artigo 		Adicionar ao Meu Espaço

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

Younes, A. ; Hilden, P. ; Coiffier, B. ; Hagenbeek, A. ; Salles, G. ; Wilson, W. ; Seymour, J.F. ; Kelly, K. ; Gribben, J. ; Pfreunschuh, M. ; Morschhauser, F. ; Schoder, H. ; Zelenetz, A.D. ; Rademaker, J. ; Advani, R. ; Valente, N. ; Fortpied, C. ; Witzig, T.E. ; Sehn, L.H. ; Engert, A. ; Fisher, R.I. ; Zinzani, P.-L. ; Federico, M. ; Hutchings, M. ; Bollard, C. ; Trneny, M. ; Elsayed, Y.A. ; Tobinai, K. ; Abramson, J.S. ; Fowler, N. ; Goy, A. ; Smith, M. ; Ansell, S. ; Kuruvilla, J. ; Dreyling, M. ; Thieblemont, C. ; Little, R.F. ; Aurer, I. ; Van Oers, M.H.J. ; Takeshita, K. ; Gopal, A. ; Rule, S. ; de Vos, S. ; Kloos, I. ; Kaminski, M.S. ; Meignan, M. ; Schwartz, L.H. ; Leonard, J.P. ; Schuster, S.J. ; Seshan, V.E.

Annals of oncology, 2017-07, Vol.28 (7), p.1436-1447 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
8
Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study
Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study

Gibson, Todd M ; Morton, Lindsay M ; Shiels, Meredith S ; Clarke, Christina A ; Engels, Eric A

AIDS (London), 2014-09, Vol.28 (15), p.2313-2318 [Periódico revisado por pares]

England

Texto completo disponível

Citações Citado por
9
Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma
Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma

Nastoupil, Loretta J ; Bartlett, Nancy L

Journal of clinical oncology, 2023-02, Vol.41 (4), p.903-913 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por
10
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

Sehn, Laurie H, Dr ; Chua, Neil, MD ; Mayer, Jiri, Prof ; Dueck, Gregg, MD ; Trněný, Marek, Prof ; Bouabdallah, Kamal, MD ; Fowler, Nathan, MD ; Delwail, Vincent, MD ; Press, Oliver, Prof ; Salles, Gilles, MD ; Gribben, John, Prof ; Lennard, Anne, MBBS ; Lugtenburg, Pieternella J, MD ; Dimier, Natalie, MSc ; Wassner-Fritsch, Elisabeth, PharmD ; Fingerle-Rowson, Günter, MD ; Cheson, Bruce D, Prof

The lancet oncology, 2016-08, Vol.17 (8), p.1081-1093 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (5.255)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (5.735)
  2. magazinearticle  (11)
  3. Anais de Congresso  (4)
  4. Livros  (2)
  5. Book Chapters  (1)
  6. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de1969  (54)
  2. 1969Até1981  (484)
  3. 1982Até1994  (1.257)
  4. 1995Até2008  (2.437)
  5. Após 2008  (1.528)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (5.431)
  2. Japonês  (685)
  3. Alemão  (123)
  4. Francês  (74)
  5. Espanhol  (60)
  6. Chinês  (17)
  7. Russo  (12)
  8. Português  (10)
  9. Holandês  (8)
  10. Italiano  (7)
  11. Norueguês  (5)
  12. Hebraico  (2)
  13. Serbian  (2)
  14. Tcheco  (2)
  15. Croatian  (2)
  16. Sueco  (1)
  17. Dinamarquês  (1)
  18. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.